Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial - Lam, S W; de Groot, S M; Honkoop, A H (Eur J Cancer, 2014)
et al.